Skip to main content
. Author manuscript; available in PMC: 2020 May 18.
Published in final edited form as: Bioconjug Chem. 2018 Oct 24;29(12):3937–3966. doi: 10.1021/acs.bioconjchem.8b00548

Figure 2. Passive immunotherapy strategies for brain cancer using anti-angiogenic antibodies.

Figure 2.

VEGFA binding to VEGFR2 triggers an increase in paracellular permeability, downregulation of tight junctional proteins, and the promotion of angiogenesis. Anti-VEGFA antibodies can bind to VEGFA and prevent angiogenesis thus inhibiting tumor growth and survival. Adapted from: 51. Abbreviations: VEGF – vascular endothelial growth factor; VEGFR – VEGF receptor.